AUCTORES
Review Article | DOI: https://doi.org/10.31579/2690-8808/094
Associate Professor of Pharmacology via Sant’ Andrea 32, 56127 Pisa, Italy.
*Corresponding Author: Gian Maria Pacifici, Associate Professor of Pharmacology via Sant’ Andrea 32, 56127 Pisa, Italy.
Citation: Gian Maria Pacifici, (2022) Clinical pharmacology of lorazepam in infants and childrenJ. Clin Case Rep and Stu 3(1); DOI: 10.31579/2690-8808/094
Copyright: © 2022 Gian Maria Pacifici, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 11 October 2021 | Accepted: 05 November 2021 | Published: 03 January 2022
Keywords: lorazepam; efficacy and safety; adverse-effects; metabolism; drug interaction; pharmacokinetics; treatment; trials; placenta; breast-milk; infants; children
Lorazepam is a benzodiazepine has antiepileptic activity; it may be administered intravenously, intramuscularly, orally, by intranasal or buccal application and following oral dosing it is well absorbed. In infants, the initial intravenous dose of lorazepam is 100 µg/kg and in children the initial oral and intravenous dose is 50 to 100 µg/kg and the dose varies according to the child age. Lorazepam has been found efficacy and safe in infants and children but it may induce adverse-effects. Lorazepam is a racemate and the R and S enantiomers are conjugated with glucuronic acid in human liver microsomes and the respective Km and Vmax values are 29+8.9 and 36+10 µM and 7.4+1.9 and 10+3.8 pmol/min*mg. Lorazepam interacts with drugs and the interaction may affect the activity or metabolism of lorazepam. The pharmacokinetics of lorazepam have been studied in infants and children and in diseased children. In infants and children the elimination half-life is about 15 hours and it is about 24 hours and about 37 hours in children with severe malaria and convulsions following intravenous and intramuscular administration, respectively. The treatment and trials with lorazepam have been studied in infants and children. Lorazepam freely crosses the human placenta and poorly migrates into the breast-milk. The aim of this study is to review the published data on lorazepam dosing, efficacy and safety, adverse-effects, metabolism, interaction with drugs, pharmacokinetics, treatment and trials in infants and children and the lorazepam transfer across the human placenta and migration into the breast-milk.
Running title: Lorazepam in infants and children.
The success of the first benzodiazepine, chlordiazepoxide (Librium®), in 1960 triggered the development of a number or related products including diazepam (licensed in 1963) and lorazepam (licensed a year later). They are widely, and liberality, used to treat anxiety before it came to be accepted that such use should always be limited to the lowest possible dose for the shortest possible time. Dependence can become a serious problem, even with careful prescribing. Lorazepam is well absorbed when taking by mouth, conjugated into an inactive glucuronide in the liver, and then excreted in the urine by glomerular filtration. The elimination half-life in the neonatal period is 30 to 50 hours (two to three times as long as in adults). The tissue levels of lorazepam exceed plasma levels and the distribution volume is about 1.3 L/kg. Most benzodiazepines are of limited value in long-term treatment of epilepsy but have an important role in the management of prolonged seizures. Diazepam was the first to be widely used. Clonazepam, lorazepam, and midazolam have all been used. There is, however, continuing concern that, while the benzodiazepine may well abolish the physical signs of the seizure, electrical seizure activity may still sometimes persist. Rapid intravenous administration in the infant can sometimes precipitate hypotension, respiratory depression, and abnormal seizure-like movements, especially in response to the first dose given. Withdrawal symptoms are also very common after sustained use even if the dose given is lowered slowly. Lorazepam readily crosses the placenta, but there is no evidence of teratogenicity. Maternal use, particularly if high doses are used, in the third trimester or during labour may cause hypothermia, lethargy, poor feeding, or neonatal withdrawal. Lorazepam is excreted into breast-milk in small amounts (about 5 to 10% of the maternal dose). Breastfeeding may further sedate an already affected infant in the immediate postnatal period but sustained use during lactation does not seem to cause noticeable drowsiness [1]. Lorazepam is used for the acute management of infants with seizures refractory to conventional therapy. Lorazepam is incompatible with fat emulsion, aztreonam, caffeine citrate, and imipenem/cilastatin [2].
The literature search was performed electronically using PubMed database as search engine and the following key words were used: “lorazepam dosing infants, children”, “lorazepam efficacy safety infants, children”, “lorazepam adverse-effects infants, children”, “lorazepam metabolism”, “lorazepam drug interactions”, “lorazepam pharmacokinetics infants, children”, “lorazepam treatment infants, children”, “lorazepam trials infants, children”, “lorazepam placental transfer”, and “lorazepam breast-milk”. In addition, the books: Neonatal Formulary [1], NEOFAX® by Young and Mangum [2], and The British National Formulary for Children [3] are consulted.
Administration schedules of lorazepam to infants and children
Administration to infants [1]
Dose: A single 100 µg/kg dose usually stop all visible seizures activity within 10 min. Whist this can be repeated after 10 min the long elimination half-life in early infancy increases the risk of sedation and respiratory depression.
Route of administration
Lorazepam is normally given by slow intravenous infusion over 3 to 5 min. The buccal and intranasal routes, whilst not well studied, do not seem to be almost equally effective (at least in infants more than a few weeks old). Lorazepam can also be given by mouth, but intramuscular administration is painful and best avoided. Sustained infusion can cause a progressive accumulation of the potentially toxic excipient propylene glycol.
Administration to children [3] Oral premedication.
Children aged 1 month to 11 years. Give: 50 to 100 µg/kg (maximum per dose = 4 mg). The dose should be given at least 1 hour before procedure, and the same dose may be given the night before procedure in addition to, or to replace, dose before the procedure.
Children aged 12 to 17 years. Give: 1 to 4 mg, to be given at least 1 hour before the procedure, the same dose may be given at night before the procedure in addition to, or to replace, dose before the procedure. Intravenous administration for the treatment of premedication
Children. Give: 50 to 100 µg/kg (maximum per dose = 4 mg), to be administered 30 to 45 min before the procedure .Intravenous administration for the treatment of the status epilepticus, febrile convulsions, or convulsions caused by poisoning
Children aged 1 month to 11 years. Give: 100 µg/kg (maximum per dose = 4 mg) for 1 dose, and then 100 µg/kg after 10 min (maximum per dose = 4 mg) if required for 1 dose, to be administered into a large vein.
Children aged 12 to 17 years. Give: 4 mg for 1 dose, and then 4 mg after 10 min if required for 1 dose, to be administered into a large dose.
Efficacy and safety of lorazepam in children
Lorazepam has been found efficacy and safe in children and the most common adverse-effects are somnolence (7.7%) and insomnia (7.7%), and almost all adverse-effects are mild or moderate in severity [4]. Intranasal lorazepam is effective, safe, and provides a less invasive alternative to intramuscular paraldehyde in children with protracted convulsions [5]. Intravenous lorazepam is the first-line therapy in preference to intravenous diazepam in children with convulsive status epilepticus [6]. Lorazepam is superior to intravenous or non-intravenous diazepam, and intravenous lorazepam is at least as effective as non-intravenous midazolam in treating paediatric status epilepticus [7]. Lorazepam induces the most sedation immediately after surgery compared to diazepam and trimeprazine [8].
Common or very common adverse-effects caused by lorazepam in infants and children [3]
Apnoea, asthenia, coma, disinhibition, extrapyramidal symptoms, hypothermia, memory loss, speech slurred, and suicide attempt.
Uncommon adverse-effects caused by lorazepam in infants and children [3]
Allergic dermatitis, constipation, and sexual dysfunction.
Rare or very rare adverse-effects caused by lorazepam in infants and children [3]
Agranulocytosis, hyponatraemia, pancytopenia, and thrombocytopenia.
Metabolism of lorazepam
The kinetics of the separate R and S enantiomers of lorazepam were characterised in human liver microsomes and by a panel of recombinant human UDP-glucuronosyltransferase enzymes. Respective mean Km and Vmax values for R- and S-lorazepam glucuronidation by human liver microsomes are 29+8.9 and 36+10 µM, and 7.4+1.9 and 10+3.8 pmol/min*mg. Microsomal intrinsic clearances were not significantly different, suggesting the in-vivo clearances of R- and S-lorazepam are likely to be similar. Both R- and S-lorazepam are glucuronidated by UGT2B4, UGT2B7, and UGT2B15, whereas R-lorazepam is additionally metabolized by the extrahepatic enzymes UGT1A7 and UGT1A10. Based on in-vitro clearances and consideration of available in-vivo and in-vitro data, UGT2B15 is likely to play an important role in the glucuronidation of R- and S-lorazepam [9]. The principal metabolite of lorazepam is lorazepam glucuronide. Blood concentrations of unconjugated lorazepam peak 1 to 4 hours following dosing. Significant concentrations persist for 24 hours and slowly decrease over the next 24 hours. About 95% of a dose of lorazepam is recovered in the urine and faeces over a period of 5 days; 74.5% is excreted in the urine as lorazepam glucuronide and 13.5% as minor metabolites [10]. Absorption of oral lorazepam is nearly complete and lorazepam glucuronide is the major metabolite and dihydrodiol derivative is another metabolite [11]. Lorazepam and lorazepam glucuronide are the only detected compounds up to 12 hours following lorazepam administration and the amount of lorazepam glucuronide exceeded that of lorazepam in blood and urine [12].
Interaction of lorazepam with drugs
Metoprolol causes a small increase in critical flicker fusion threshold with lorazepam [13]. The effect of lorazepam in doses of 2 mg and 4 mg combined with morphine 5 mg produces sedation, relief of anxiety, lack of recall, and patient acceptance [14]. Lorazepam combined with mirogabalin increases somnolence [15]. The UGT2B7 genotype affects lorazepam-valproate pharmacodynamic interaction especially in subjects who have homovariant genotypes of UGT2B7 and UGT2B15 [16]. Pre-treatment with 1 mg/kg of 4,5,6,7-tetrahydroisoxazolo [5,4-c]pyrindin-3-ol attenuates the rate-increasing effects of lorazepam on non-suppressed responding [17]. Moxonidine, when co-administered with lorazepam, produces interactions with three tasks requiring high levels of attention reduces vigilance performance, memory tasks, and visual tracking [18]. Caffeine citrate (500 mg) counteracts the lorazepam effect of reducing anxiety and making the subject feel more relaxed [19]. Lorazepam treatment should not be combined with even small quantities of alcohol because of the risk of both psychomotor impairment and possible anxiogenic effects [20]. Cimetidine increased the absorption-rate of diazepam and lorazepam [21].
Pharmacokinetics of lorazepam in infants and children
Gonzalez et al. [22] studied the pharmacokinetics of lorazepam in 145 infants and children and lorazepam was administrated intravenously. Table 1 summarized the lorazepam dose and the demographic characteristics of subjects included in the study.
CDV = central distribution volume. TBC = total body clearance. PDV = peripheral distribution volume. Q = intercompartmental clearance. %RSE = %relative standard error of estimate.
This table shows that the central median distribution volume is similar to the peripheral distribution volume and there is a remarkable interindividual variability in pharmacokinetic parameters. This variability is accounted by the wide variability of the demographic characteristics of the subjects included in the study.
Chamberlain et al. [23] investigated the pharmacokinetics of lorazepam in 168 infants and children, lorazepam was administered intravenously, the dose was computed according the subject body-weight, and the mean dose is 5.3 mg (0.16 mg/kg). Fifty-two subjects are aged 3 months to < 3>
TBC = total body clearance. DV = distribution volume.This table shows that the distribution volume of lorazepam is larger than the water volume, lorazepam is slowly eliminated from the body, and there is a remarkable interindividual variability in the pharmacokinetic parameters. This variability is accounted by the wide variation of the subject demographic characteristics.
TBC = total body clearance. DVss = distribution volume at the steady-state. β = terminal slope of the log concentration versus time profile.This table shows that lorazepam distribution volume is larger than the water volume, lorazepam is slowly eliminated, and there is a remarkable interindividual variability in the pharmacokinetic parameters. This interindividual variability is due to the wide variation of the demographic characteristics of the subjects included in the study.
Pharmacokinetics of lorazepam in diseased children
Muchohi et al. [24] studied the pharmacokinetics of lorazepam in 26 children with severe malaria and convulsions. A single dose of 0.1 mg/kg of lorazepam was administered intravenously to 15 children and intramuscularly to 11 children.
This table shows that the peak concentration, the time to achieve the peak concentration, the elimination half-life, and AUC are similar according to the two routes of lorazepam administration. Following intramuscular administration, lorazepam is rapidly and almost completely absorbed. The comparison of the pharmacokinetic parameters obtained in children with those obtained in infants and children (see tables 3 and 4) is difficult because of the different demographic characteristics of the subjects included in the studies and the diseases suffered from children.
Treatment with lorazepam in infants and children
Lorazepam is an effective agent in the treatment of neonatal seizures refractory to phenobarbital [25]. Treatment with lorazepam causes immediate cessation of seizure activity in all infants within 5 min [26]. Lorazepam is increasingly used in the treatment of refractory neonatal seizures [27]. In children, intravenous lorazepam and intravenous diazepam are efficacious for stopping seizures lasting at least 5 min [28]. Intravenous lorazepam is associated with a 3.7 times greater likelihood of seizure termination than is treatment with rectal diazepam [29]. The childhood seizure is successfully controlled 15 min after intravenous diazepam and after 5 min with intravenous lorazepam [30]. Lorazepam is a safe and effective agent to treat acute convulsions in children with status epilepticus [31]. Sublingual lorazepam is an easy and effective agent for treating serial childhood seizures at home [32]. Convulsions are controlled in 76% children treated with a single rectal dose of lorazepam and in 51% children treated with a single rectal dose of diazepam [33].
Trials with lorazepam in children
Lorazepam is the safer benzodiazepine for oral maintenance treatment of methamphetamine-induced convulsions [34]. Intravenous lorazepam is at least as effective as intravenous diazepam in treating acute tonic-clonic convulsions in children and lorazepam is associated with fewer adverse-effects [35]. Intravenous lorazepam is at least as effective as intravenous diazepam in controlling childhood seizures and is associated with fewer adverse-effects in the treatment of acute tonic-clonic convulsions [36]. Intravenous lorazepam is superior to intravenous diazepam in the treatment of paediatric status epilepticus [37]. Intranasal lorazepam has more favourable pharmacokinetics than buccal lorazepam when considering the need for the rapid blood concentrations required for seizure termination in children [38].
Transfer of lorazepam across the human placenta
Placental transfer of lorazepam evaluated as the ratio of vein umbilical to maternal vein plasma concentrations is 0.73 (range, 0.52-0.94) [39]. Lorazepam was administered intravenously at a dose of 2.5 mg to pregnant mothers before surgical induction of labour or at the beginning of the second stage of labour. Lorazepam serum concentrations in newborns are similar to those in the maternal serum and rarely exceed the maternal concentrations [40].
Migration of lorazepam into the breast-milk
Lorazepam exposure through breast-milk is small, thus the maternal drug treatment and breastfeeding are compatible [41]. Following therapeutic dosing of lorazepam, the concentration of lorazepam in the breast-milk ranges from 55.3 to 123 ng/ml [42]. Measurable concentrations of lorazepam is demonstrated in all but 1 of the 35 breast-milk samples and the mean lorazepam concentration is 2.6+1.5 ng/ml (range, 0 to 7.0) [43]. Lactating women were treated with oral lorazepam twice-daily at a dose of 2.5 mg for the first 5 days postpartum and the concentrations of free and glucuronide lorazepam are 12 and 35 ng/ml, respectively [44].
Lorazepam is a benzodiazepine has antiepileptic activity and it is used in acute management of infants, and children with seizures refractory to conventional therapy. Lorazepam may be administered intravenously, intramuscularly, orally, or by intranasal or buccal application and following oral administration lorazepam is rapidly and almost completely absorbed. The tissue level of lorazepam exceeds the plasma level and lorazepam distribution volume is about 1.3 L/kg. The initial intravenous dose of lorazepam is 100 µg/kg in infants [1]. In children, the initial oral or intravenous dose is 50 to 100 µg/kg and the dose varies according to the child age [3]. Lorazepam has been found efficacy and safe in infants and children [4-8]. Lorazepam has been found efficacy and safe in children but it may induce somnolence and insomnia and the adverse-effects are mild [4], intranasal lorazepam is efficacy and safe and it is a less invasive alternative to intramuscular paraldehyde in children with convulsions [5]. Intravenous lorazepam is the first-line therapy in preference to intravenous diazepam in treating children with convulsive status epilepticus [6], intravenous lorazepam is superior to intravenous or non-intravenous diazepam and intravenous lorazepam is effective as non-intravenous midazolam in treating paediatric status epilepticus [7], lorazepam induces the most sedation immediately after surgery compared to diazepam and trimeprazine [8], and lorazepam may induce adverse-effects [3]. The metabolism of lorazepam has been studied in man [9-12]. Lorazepam is conjugated with glucuronic acid; lorazepam is a racemate and the respective mean Km and Vmax values of R and S enantiomers of lorazepam are 29+8.9 and 36+10 µM and 7.4+1.9 and 10+3.9 pmol/min*mg in human liver microsomes. Both R- and S-lorazepam are glucuronidated by UGT2B4, UGT2B7, and UGT2B15, whereas R-lorazepam is additionally metabolized by extrahepatic enzymes UGT1A7 and UGT1A10 [9]. Blood concentrations of unconjugated lorazepam peak 1 to 4 hours following dosing, lorazepam slowly decreases from blood and 74.5% and 13.5% of the dose are excreted in the urine as lorazepam glucuronide and as minor metabolites [10]. Absorption of oral lorazepam is nearly complete, lorazepam glucuronide is the major metabolite of lorazepam, lorazepam glucuronide concentration exceeds that of lorazepam in blood and urine, and both lorazepam and lorazepam glucuronide are eliminated in the urine [11, 12]. Lorazepam interacts with drugs [13-21]. Metoprolol causes a small increase in critical flicker fusion threshold with lorazepam [13], lorazepam combined with morphine produces sedation, relief of anxiety, lack of recall, and patient acceptance [14], and lorazepam co-administered with mirogabalin increases somnolence [15]. The UGT2B7 genotype affects lorazepam-valproate pharmacodynamic interaction in subjects who have homovariant genotypes of UGT2B7 and UGT2B15 [16]. Pre-treatment with 1 mg/kg 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyrindin-3-ol attenuates the rate-increasing effects of lorazepam on non-suppressed responding [17]. The co-administration of moxonidine with lorazepam produces interactions with three tasks requiring high levels of attention, memory tasks, and visual tracking [18]. Caffeine citrate counteracts the lorazepam effect reducing anxiety and making the subjects feel more relaxed [19]. Lorazepam treatment should not be combined with alcohol because of the risk of both psychomotor impairment and possible anxiogenic effects [20], and cimetidine increases the absorption-rate of diazepam and lorazepam [21]. The pharmacokinetics of lorazepam have been studied in infants and children [22, 23] and in children with severe malaria and convulsions [24]. In infants and children, the median central and peripheral distribution volumes are 0.786 and 0.737 L/kg, respectively, indicating than the lorazepam concentrates in blood and in tissues in similar amounts [22] and the man elimination half-life ranges from 15.1 to 17.8 hours [23]. Lorazepam was administered intravenously or intramuscularly to children with severe malaria and convulsions and following intramuscularly administration lorazepam is rapidly absorbed and the mean absorption half-life of lorazepam is 0.035 hours. The mean elimination half-life is 23.7 hours following intravenous dosing and 36.9 hours following intramuscular dosing [24] suggesting that lorazepam is slowly eliminated following intramuscular administration because lorazepam slowly leaves from the muscle depot. The treatment with lorazepam in infants and children has been extensively studied [25-33]. Lorazepam is an effective agent in the treatment of neonatal seizures refractory to phenobarbital [25], lorazepam causes immediate cessation of seizures in infants within 5 min [26], and lorazepam is increasingly used in the treatment of refractory neonatal seizures [27]. In children, intravenous lorazepam and intravenous diazepam stop seizures lasting at least 5 min [28], intravenous lorazepam has a greater likelihood of seizure termination than rectal diazepam [29] and intravenous lorazepam controls childhood seizures more rapidly than intravenous diazepam [30]. Lorazepam is an effective and safe agent to treat the status epilepticus in children [31], sublingual lorazepam easily and effectively controls serial seizures in children [32], and the convulsions are controlled in 76% of children treated with single rectal lorazepam and in 51% children treated with single rectal diazepam [33]. The trials with lorazepam have studied in children [34-38]. Lorazepam is the safer benzodiazepine for oral treatment of methamphetamine-induced convulsions [34]. Intravenous lorazepam and intravenous diazepam are similarly effective agents in treating children with acute tonic-clonic convulsions but lorazepam is associated with fewer adverse-effects [35], intravenous lorazepam is as effective as intravenous diazepam in controlling childhood seizures but lorazepam is associated with fever adverse-effects in the treatment of acute tonic-clonic convulsions [36], and intravenous lorazepam is superior to intravenous diazepam in the treatment of paediatric status epilepticus [37]. Intranasal lorazepam has more favourable pharmacokinetics than buccal lorazepam in termination seizures in children [38]. Lorazepam freely crosses the human placenta [39, 40], and lorazepam poorly migrates into the breast-milk [41-44].
In conclusion, lorazepam is a benzodiazepine and is the most active benzodiazepine in treating refractory convulsions resistant to conventional therapy in infants and children. Lorazepam may be administered intravenously, intramuscularly, orally or by intranasal and buccal application and following oral dosing it is rapidly absorbed. In infants, the initial intravenous dose is 100 µg/kg and the initial oral or intravenous dose is 50 to 100 µg/kg in children. Lorazepam has been found efficacy and safe in infants and children but it may induce adverse-effects. Lorazepam is glucuronidated by UGT2B4, UGT17A, and UGT1A10 and lorazepam interacts with drugs and the interaction with drugs affects lorazepam effects and metabolism. The pharmacokinetics of lorazepam have been studied in infants and children and in children with severe malaria and convulsions. The elimination half-life of lorazepam ranges from 15.1 to 17.8 hours in infants and children. In these diseased children, the mean elimination half-life is 23.7 hours following intravenous administration and 36.9 hours after intramuscular administration. The treatment and trials with lorazepam have been extensively studied and lorazepam freely crosses the placenta and poorly migrates into the breast-milk. The aim of this study is to review the clinical pharmacology of lorazepam in infants and children.
The authors declare no conflicts of financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employments, gifts, and honoraria.
This article is a review and drugs have not been administered to men or animals.
The author thanks Dr. Patrizia Ciucci and Dr. Francesco Varricchio, of the Medical Library of the University of Pisa, for retrieving the scientific literature.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
I would like to offer my testimony in the support. I have received through the peer review process and support the editorial office where they are to support young authors like me, encourage them to publish their work in your esteemed journals, and globalize and share knowledge globally. I really appreciate your journal, peer review, and editorial office.